Avammune Therapeutics develops small molecule modulators targeting the innate immune system to treat cancer. The company integrates novel target biology, immunology, and computational chemistry to create a proprietary pipeline of drug candidates. Their focus includes developing best-in-class and first-in-class drugs for oncology applications.